Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

Post Liver Transplant Clinical Trial

Official title:
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant

Status Completed

Clinical Trial Summary

This is an open-label, single-arm study of sofosbuvir (GS-7977) and ribavirin (RBV) in adults who have had a liver transplant which has become re-infected with hepatitis C. The treatment period is 24 weeks with up to 48 weeks of follow up. The total time in this study will last up to 72 weeks not including the screening visit.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01687270
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	November 2012
Completion date	August 2014

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06304467` - CM for Patients With ALD After Liver Transplant	N/A
Active, not recruiting	`NCT05063071` - Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant	Phase 4
Active, not recruiting	`NCT03386305` - Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant	Phase 2/Phase 3